Skip to content

Weibo

US · WB #2950 by market cap Listed 2014
5.19 -0.14 -2.63%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Quant vs Street three independent views, side by side

StockVane factor grade
A-
Momentum strategy signal
Strong Sell
Analyst consensus
Hold

Signals diverge - worth digging into why.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 4 analysts

Hold
Avg price target 7.25 +39.7%
Price target rangecurrent 5.19
Low6.50
Avg7.25
High8.00
Buy 0% Hold 75% Sell 25%
Recent ratings (9)
DateFirmAnalystRatingTarget
2026-10-23 Goldman Sachs -- Hold 6.70
2026-08-24 J.P. Morgan -- Hold 8.00
2026-08-21 BofA Securities -- Sell 6.50
2026-08-20 Citi -- Hold 7.80
2026-08-20 Goldman Sachs -- Hold 7.80
2026-06-05 J.P. Morgan -- Hold 9.00
2026-05-29 BofA Securities -- Sell 7.00
2026-05-28 Jefferies -- Buy 9.80
2025-11-20 BofA Securities -- Sell 8.70

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q2 2026-08-19 -- ±10.88% -1.32% (in line)
2026/Q1 2026-05-28 -- ±10.83% -2.97% (in line)
2025/Q4 2026-03-18 -- ±5.95% -10.65% (beat)
2025/Q3 2025-11-18 -- ±5.28% -0.10% (in line)
2025/Q2 2025-08-14 -- ±6.86% +11.28% (beat)
2025/Q1 2025-05-21 -- ±5.75% +4.28% (in line)
2024/Q4 2025-03-13 -- ±7.15% -3.16% (in line)
2024/Q3 2024-11-19 -- ±8.51% +6.35% (in line)
2024/Q2 2024-08-22 -- ±8.04% -1.52% (in line)
2024/Q1 2024-05-23 -- ±8.01% -0.90% (in line)
2023/Q4 2024-03-14 -- ±10.67% -1.96% (in line)
2023/Q3 2023-11-09 -- ±7.58% -5.72% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Weibo discussion 0 comments

Add a comment